Erminia Massarelli, MD
Medical Oncology · Duarte, CANPI 1982855326
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (48.2%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 26 manufacturers reported payments, led by AstraZeneca at 39.7% of the total. Among medical oncology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 224 payments — averaging $786.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$70K
- Merck$18K
- Janssen Scientific Affairs, LLC$16K
- Johnson & Johnson$12K
- Takeda Pharmaceuticals U.S.A., Inc.$11K
- Sanofi$9K
- plus $40K from 20 others
Across 364 payments — averaging $19,437 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$1.2M
- GSK$1.1M
- Merck$1M
- Pfizer$767K
- Janssen Research & Development, LLC$607K
- Eli Lilly$600K
- plus $1.8M from 14 others
What the payments were for
- Consulting fees$77,07844%
- Speaking & faculty fees$84,91948%
- Travel & lodging$7,7004%
- Food & beverage$6,3844%
- Education$2000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 83 | $69,908 |
| Merck | 18 | $18,201 |
| Janssen Scientific Affairs, LLC | 12 | $15,857 |
| Johnson & Johnson | 21 | $12,464 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $10,765 |
| Sanofi | 3 | $8,757 |
| E.r. Squibb & Sons, L.L.C. | 15 | $8,520 |
| Mirati Therapeutics, Inc. | 10 | $8,074 |
| Eli Lilly | 4 | $7,650 |
| AbbVie | 5 | $5,840 |
| Daiichi Sankyo Inc. | 8 | $3,900 |
| Gilead | 3 | $2,592 |
| Janssen Global Services, LLC | 1 | $1,265 |
| Catalyst Pharmaceuticals, Inc. | 1 | $1,125 |
| Lilly USA, LLC | 3 | $201 |
| Pfizer | 8 | $195 |
| Galvanize Therapeutics, Inc | 3 | $169 |
| Regeneron Healthcare Solutions, Inc. | 4 | $164 |
| Astrazeneca UK Limited | 3 | $158 |
| Genentech USA, Inc. | 2 | $132 |
| Tempus AI, Inc | 5 | $118 |
| Array Biopharma Inc | 3 | $80 |
| Regeneron | 1 | $59 |
| Genentech, Inc. | 1 | $38 |
| Bristol Myers Squibb | 1 | $32 |
| Pharmacosmos Therapeutics Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$176,280 in reported general payments places this provider in the 90th percentile of 379 medical oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TagrissoOsimertinib Mesylate | 25 | $397,910 |
| Prochlorperazine Maleate | 18 | $195 |
| Ondansetron Hcl | 21 | $99 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso | $69,908 | $397,91025 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 379 medical oncology providers in California.
Other medical oncology in Duarte
- Daneng LiDuarte$467K
- Howard WestDuarte$426K
- Christine LovlyDuarte$362K
- Marwan FakihDuarte$203K
- Ravi SalgiaDuarte$142K
- Tanya DorffDuarte$136K
- Karen ReckampDuarte$132K
- Cy SteinDuarte$122K
- Joseph ChaoDuarte$110K
- Stephen SherwinSan Francisco$6.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.